Literature DB >> 22377951

HBOC attenuates intense exercise-induced cardiac dysfunction.

T Li1, D Zhu, R Zhou, W Wu, Q Li, J Liu.   

Abstract

The purpose of this study was to investigate whether hemoglobin-based oxygen carrier (HBOC) could protect the heart from intense exercise-induced myocardial dysfunction. Adult male Sprague-Dawley rats were subjected to 5-h intense prolonged running on treadmill with or without HBOC pre-treatment. Immediately after exercise, the heart rate (HR) and oxygen delivery capacity of the blood were measured. After 1 h of rest, echocardiography was performed to assess the post-exercise cardiac function. Then all the hearts were isolated and perfused using the Langendorff model for 1 h. Our results proved that pronged exercise caused significant LV dysfunction, while HBOC pre-treatment attenuated such a damage, as evidenced by the increased oxygen delivery, cardiac fractional shortening (FS), rate-pressure product (RPP), ± dp/dt and coronary flow rate (CF) and decreased myocardial necrosis. The releases of cardiac enzymes, including creatine kinase-MB (CK-MB) and cardiac troponin-I (cTnI) were markedly reduced. No significant difference of cardiac infarct size was observed among groups. In addition, HBOC significantly elevated superoxide dismutase (SOD) activity and decreased hydrogen peroxide (H2O2) formation, which indicated the exercise-induced cardiac oxidative damage was inhibited. In conclusion, HBOC pre-treatment showed a promising cardioprotective effect on prolonged exercise-induced cardiac dysfunction, which was probably associated with its ability to decrease myocardium oxidative stress. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22377951     DOI: 10.1055/s-0031-1301311

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  7 in total

1.  Angiotensin-converting enzyme inhibitor captopril reverses the adverse cardiovascular effects of polymerized hemoglobin.

Authors:  Tao Li; Ronghua Zhou; Yusheng Yao; Qian Yang; Cheng Zhou; Wei Wu; Qian Li; Zhen You; Xiaolin Zhao; Linhui Yang; Chen Li; Da Zhu; Yanhua Qiu; Ming Luo; Zhaoxia Tan; Huan Li; Yanfang Chen; Gu Gong; Yuan Feng; Ke Dian; Jin Liu
Journal:  Antioxid Redox Signal       Date:  2014-03-06       Impact factor: 8.401

2.  High-Dose Polymerized Hemoglobin Fails to Alleviate Cardiac Ischemia/Reperfusion Injury due to Induction of Oxidative Damage in Coronary Artery.

Authors:  Qian Yang; Wei Wu; Qian Li; Chan Chen; Ronghua Zhou; Yanhua Qiu; Ming Luo; Zhaoxia Tan; Shen Li; Gang Chen; Wentao Zhou; Jiaxin Liu; Chengmin Yang; Jin Liu; Tao Li
Journal:  Oxid Med Cell Longev       Date:  2015-06-16       Impact factor: 6.543

3.  An inhibitor of the δPKC interaction with the d subunit of F1Fo ATP synthase reduces cardiac troponin I release from ischemic rat hearts: utility of a novel ammonium sulfate precipitation technique.

Authors:  Mourad Ogbi; Ijeoma Obi; John A Johnson
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

4.  Artificial oxygen carriers: a new future?

Authors:  Donat R Spahn
Journal:  Crit Care       Date:  2018-02-23       Impact factor: 9.097

5.  H2O2 Signaling-Triggered PI3K Mediates Mitochondrial Protection to Participate in Early Cardioprotection by Exercise Preconditioning.

Authors:  Yang Yuan; Shan-Shan Pan; Dong-Feng Wan; Jiao Lu; Yue Huang
Journal:  Oxid Med Cell Longev       Date:  2018-07-25       Impact factor: 6.543

6.  Altered expression levels of autophagy-associated proteins during exercise preconditioning indicate the involvement of autophagy in cardioprotection against exercise-induced myocardial injury.

Authors:  Jian-Qi Yuan; Yang Yuan; Shan-Shan Pan; Ke Cai
Journal:  J Physiol Sci       Date:  2020-02-17       Impact factor: 2.781

7.  Exercise Preconditioning Plays a Protective Role in Exhaustive Rats by Activating the PI3K-Akt Signaling Pathway.

Authors:  Jingjing Li; Peng Xu; Yang Wang; Zheng Ping; Xuebin Cao; Yu Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-21       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.